Background and Purpose-Because several new devices for mechanical thrombectomy have become available, the outcomes of patients undergoing endovascular treatment for acute ischemic stroke are expected to improve in the United States. We performed this analysis to evaluate trends in utilization of endovascular treatment and associated rates of death and disability among acute ischemic stroke patients over a 6-year period, including further assessment within age strata. Methods-We obtained data for patients admitted to hospitals in the United States from 2004 to 2009 with a primary diagnosis of ischemic stroke using a large national database. We determined the rate and pattern of utilization, and associated in-hospital outcomes of endovascular treatment among ischemic stroke patients and further analyzed trends within age strata. Outcomes were classified as minimal disability, moderate to severe disability, and death based on discharge disposition and compared between , with the patients aged Ն85 years having the lowest rate of utilization (0.2%). The rates of intracranial hemorrhage remained unchanged throughout the 6 years. In multivariate logistic regression analysis, after adjusting for age, gender, presence of hypertension, congestive heart failure, renal failure, and secondary intracranial hemorrhages, there was no difference in the rate of minimal disability between the 2 study intervals (2004 -2007 vs 2008 -2009; odds ratio, 0.8; 95% confidence interval, 0.7-1.04; Pϭ0.11). Mortality decreased while moderate to severe disability increased for patients treated during 2008 to 2009 (odds ratio, 0.7; 95% confidence interval, 0.6 -0.9; Pϭ0.007; and odds ratio, 1.4; 95% confidence interval, 1.2-1.7; Pϭ0.0002). Conclusion-There has been a significant increase in the proportion of acute ischemic stroke patients receiving endovascular treatment over the 6 years and reduction in in-hospital mortality. Our results highlight the need to implement endovascular techniques in a balanced manner across various age groups that also results in the reduction of disability in addition to mortality. (Stroke. 2012;43:00-00.)
U ntil 2004, the only Food and Drug Administrationapproved treatment option for patients with acute ischemic stroke was intravenous tissue plasminogen activator administration if patients presented within 3 hours of symptoms onset. 1 Endovascular treatment has concurrently existed on a very limited scale for acute ischemic stroke. In general, endovascular treatment could be subdivided into pharmacological modalities such as intra-arterial tissue plasminogen activator or mechanical modalities such as the snare device, balloon angioplasty, stent placement, and microcatheter/wire manipulation. [2] [3] [4] [5] [6] Food and Drug Administration approval of the Mechanical Embolus Removal in Cerebral Ischemia (MERCI) concentric retriever (Concentric Medical, Mountain View, CA) in August 2004, introduced endovascular treatment including thrombectomy of acute ischemic stroke in practice and resulted in new trials of mechanical thrombectomy devices in acute stroke. 3 The subsequent approval of the Penumbra system (Penumbra, Alameda, CA) in January 2008 contributed to rapid evolution in the treatment of acute ischemic stroke over the past 6 years. However, there is a paucity of studies addressing the rates and patterns of utilizations and associated outcomes in patients treated in the general practice. In the current study, we studied the trend of endovascular treatment from 2004 to 2009, including further assessment within age strata. We also determined overall and subgroup clinical outcomes using the Nationwide Inpatient Sample database. Our study was directed toward providing a comprehensive assessment of multimodal endovascular treatment including intra-arterial thrombolysis and mechanical thrombectomy at a national level.
Materials and Methods

Dataset and Patient Demographics
We analyzed the data from Nationwide Inpatient Sample data files provided by the Agency for Healthcare Research and Quality, the largest all-payer inpatient care database in the United States, for the years 2004 to 2009. Nationwide Inpatient Sample represents Ϸ20% stratified random sample of all patients admitted at nonfederal hospitals, including those managed by city and state governments and for-profit and not-for-profit organizations. Hospital characteristics, geographic region, ownership, location (urban or rural), teaching status, and bed size are used for stratification in an attempt to create a sample that is maximally representative of hospitalizations in the United States. Detailed information regarding the dataset is publically available at http://www.hcup-us.ahrq.gov.
Using International Classification of Disease, Clinical Modification, 9th revision (ICD-9 CM) primary diagnosis codes (433-437.1), we first identified patients with acute ischemic stroke. Data regarding patient demographic and clinical characteristics including age, gender, race/ ethnicity, and comorbid conditions, including hypertension, diabetes mellitus, congestive heart failure, renal failure, coagulopathy, chronic lung disease, and valvular heart disease, were acquired from Agency for Healthcare Research and Quality comorbidity data files. In-hospital medical complications were identified by ICD-9-CM secondary diagnosis codes. Patients undergoing gastronomy or mechanical ventilation were identified by ICD-9 procedure codes as follows: acquired pneumonia ( We also estimated the length of stay and total hospital charges in patient groups. Discharge outcome was categorized into home discharge as minimal disability, any other discharge status was described as moderate to severe disability, and in-hospital mortality as described in a previous publication. 7 We determined the proportion of patients in the 2 time groups admitted to the various types of hospitals based on geographic location and teaching status.
Determination of Endovascular Treatment
We used a combination of ICD-9 CM procedure and Medicare severity diagnosis-related group codes to identify the patients who were treated with endovascular treatment. Patients undergoing mechanical thrombectomy were identified using the ICD-9 procedure code 39.74, as previously described by Brinjikji et al. 8 We also used (Medicare severity diagnosis-related group code 543) codes for identifying patients with percutaneous mechanical thrombectomy for ischemic stroke. If a patient received ICD-9 CM code 99.10 and subsequent ICD-9 CM 00.41 to 00.43, then the patient also was labeled as receiving endovascular treatment. Most endovascular treatments are a combination of intra-arterial thrombolytics and thrombectomy. 9 Therefore, identifying these patients as those treated with endovascular treatment without further stratifications provides a more accurate ascertainment.
Statistical Analysis
Statistical analyses were performed by using the SAS software version 9.1 (SAS Institute, Cary, NC) to convert raw counts generated from the Nationwide Inpatient Sample database into weighted counts and generate national estimates. Descriptive analysis was performed providing frequencies with 95% confidence intervals (CI) and means for categorical and continuous variables. Comparisons were performed using Fisher exact probability test and probability values were noted. The conventional threshold of statistical significance (PϽ0.05) was used to determine the significance of variables in our findings in light of the potential undue effect of a very large sample size. SAS procedures SURVEYMEANS, SURVEYFREQ, and SURVEYLOGISTIC were utilized for descriptive analyses and modeling procedures.
We performed (2008) devices. Inhospital outcomes included hospital complications, discharge disposition, hospital charges, and length of hospitalization. We also performed multivariate stepwise logistic regression analysis to assess the outcome of patients treated with any endovascular treatment (using any modality). Logistic regression model was adjusted for age, gender, co-morbidities, and hospital location and teaching status. In-hospital mortality was analyzed in a dichotomized manner for all patients treated with endovascular treatment, whereas minimal vs moderate/severe disability was assessed as a dichotomized variable for all patients discharged alive. We performed trend analysis for endovascular treatment per year from 2004 to 2009 in the overall adult population and within age strata (10-year strata), and we plotted the in-hospital mortality every year within the endovasculartreated patients.
Results
Baseline Demographic and Clinical Characteristics
Of the 3 292 842 patients with acute ischemic stroke, 72 342 (2.2%) received intravenous tissue plasminogen activator, Patients within the post-MERCI period were less likely to have hypertension (Pϭ0.0109), congestive heart failure (Pϭ0.0017), and renal failure (Pϭ0.0055), respectively. There was no statistical difference for in-hospital medical complications, including rates of secondary intracranial hem- orrhages between the 2 study periods (Table) . Length of stay decreased (PϽ0.0001) and total hospital charges increased (PϽ0.0001) in the post-Penumbra period compared with the post-MERCI period.
Clinical Outcomes at Discharge
In-hospital mortality decreased in patients treated during the post-Penumbra era (Figure 2) 
Trend of Endovascular Treatment Use by Age Strata and Years
Utilization of endovascular treatment increased from 0.1% to 0.6% (PϽ0.0001) from 2004 to 2009, with a similar trend observed for intravenous tissue plasminogen activator over the years (Figure 1 ). When we compared treatment by age strata, we observed that patients younger than 45 years had the highest rate of utilization (1.3%), whereas patients aged Ն85 years had the lowest rate of utilization of endovascular treatment (0.2%) (Figure 3 ). In-hospital mortality decreased significantly over the 6 years in the endovascular-treated patients (Pϭ0.0096; Figure 2 ).
Discussion
We analyzed the in-hospital outcomes of acute ischemic stroke patients in the United States selected for endovascular treatment since Food and Drug Administration approval of the MERCI retriever device. We found that the utilization of endovascular treatment increased from 0.1% to 0.6% from 2004 to 2009, with prominent differences in utilization increasing within age strata. A comparison of the post-MERCI and the post-Penumbra period suggested that in-hospital mortality had decreased whereas moderate to severe disability had increased in patients (Table) . The results do not reflect on individual devices, but rather the time period that signifies greater availability and acceptance of new endovascular devices like the MERCI and Penumbra system. Most endovascular treatments are a combination of intra-arterial thrombolytics and thrombectomy. Our study is unique in that it incorporates intra-arterial thrombolysis patients in addition to those treated with mechanical thrombectomy, which leads to a more accurate approximation of overall endovascular treatments nationally, unlike previous studies. 2 Such patient identification was made possible because of the availability of the new ICD-9 CM procedure and diagnosis-related group codes in 2004. We identified these patients as those treated with endovascular treatment without further stratifications to provide an accurate reflection. The increase in the number of patients who received endovascular treatment for acute ischemic stroke from 2004 to 2009, might be explained by an increasing number of comprehensive stroke centers, increased physician acceptance, advanced imaging modalities, and better reimbursement for stroke hospitalizations subsequent to mechanical thrombectomy. We think that patient identification in expanded time windows because of higher utility of advanced imaging modalities may have contributed to the observed increase. The American Heart Association statement suggests that computed tomography perfusion may be used to select patients for intravenous thrombolysis treatment beyond a strict 3-hour time window. 10 Therefore, a larger number of patients who present after 6 hours of symptom onset may be receiving endovascular treatment. However, the exact contribution of each of the factors is not measurable.
We found a prominent difference in utilization of endovascular treatment increases within age strata. The rate of utilization of endovascular treatment was much lower among older patients with ischemic stroke. Part of this difference in implementation may be attributable to the relatively higher rate of death and disability associated with endovascular treatment among older patients observed in clinical studies. The pooled analysis of the MERCI and Multi-MERCI trials demonstrated that increased age was associated with worse outcomes and increased risk of mortality. 11, 12 Although several studies have demonstrated a higher rate of death and disability among older patients compared with younger patients undergoing endovascular treatment, 8 it remains unclear whether the outcome of older patients treated with endovascular treatment is better than for those who do not undergo any treatment. Zacharatos et al 13 in a case-control study found that after adjusting for initial National Institutes of Health Stroke Scale score and age, patients aged 80 years or older with acute ischemic stroke who had endovascular treatment had Ϸ5.8-fold higher odds of achieving a favorable outcome at discharge compared with those who received nonthrombolytic medical treatment. Similarly, patients treated with intravenous tissue plasminogen activator or endovascular treatment had Ϸ7.2-fold higher odds of experiencing neurological improvement at 7 days or discharge, thus supporting a role for acute thrombolytic therapies in patients aged 80 years or older.
We found that in-hospital mortality had decreased, whereas moderate to severe disability had increased in patients treated in the post-Penumbra period compared with the post-MERCI period. The interpretation of this observation is that newer endovascular techniques and devices have increased survival, but at the cost of greater moderate to severe disability. Besides the increased costs of health care and support services in patients with disability, the acceptability of such an outcome for patients and families needs to be considered. Moderate to severe disability despite more advanced methodology to recanalize occluded arteries may be secondary to increased rates of futile recanalizations. Hussein et al 14 showed that futile recanalization is a relatively common occurrence after endovascular treatment, especially among patients with severe deficits and elderly patients. It is also possible that improvement in ancillary care such as neurocritical care and adherence to best practices have improved survival. However, it appears to be an important challenge for successful implementation of newer endovascular techniques to reduce disability in addition to mortality. These results highlight the unsolved issues regarding the best selection criteria for identifying patients who could benefit from endovascular treatment. The results also identify gaps in implementation of new devices into routine practice in a manner that is consistent with clinical benefit observed in trials.
We have used primary ICD-9-CM diagnostic and procedure codes for ischemic stroke admission and thrombolytic use. These codes have shown a true positive rate of up to 84% in previous studies for identification of stroke admission, 15 and a sensitivity of 55% and specificity of 98% for thrombolytic use. 16 The high specificity of both codes suggests patient identification is most likely accurate, but there is potential for underestimation. The database lacks the standard severity scales, including National Institutes of Health Stroke Scale and modified Rankin scale scores, and therefore limits our ability to adjust for severity of neurological deficits or recanalization. Although our results are valid for overall treated population, the data do not allow us to identify subgroups defined by initial severity of deficits and time to treatment that are at highest likelihood for futile recanalization. We are unable to provide mechanistic explanation for the observed findings in the absence of procedure-specific information. The discharge functional outcome cannot be measured with the available data, and the closest index is the destination of discharge. In a previous analysis, we found that discharge to nursing home had a positive predictive value of 95%, for modified Rankin Scale score of 2 to 6 at 3 months. 17 However, the conclusions regarding disability observed in the study sample need to be interpreted with this understanding.
There appears to be a significant increase in the proportion of acute ischemic stroke patients receiving endovascular treatment over the past 6 years in the United States. Our results highlight the need to implement endovascular techniques in a balanced manner across various age groups that also result in the reduction of disability in addition to mortality. More advanced imaging modalities for better patient selection, improved devices and operator experience, and improvement in ancillary care will potentially continue to improve outcomes and survival in endovascular stroke patients.
